Epistem Ltd

Epistem Ltd is a UK-based biotechnology company focused on providing innovative preclinical and clinical research services to enhance drug discovery and development across various therapeutic areas. Founded in 2000 in Manchester, UK, Epistem Ltd specializes in preclinical and clinical research services, focusing primarily on oncology and inflammatory diseases. The company has undergone several funding rounds, with its most recent PIPE round occurring on May 1, 2014, raising GBP 6. 50 mn, which matches its total funding to date.

The company is led by CEO Cath Booth, who has a history in the biotech sector. Epistem Ltd offers a comprehensive suite of innovative preclinical and clinical research services designed to support drug discovery, development, and clinical pipelines. Their core product offerings include in vitro and in vivo models focusing on oncology, inflammatory diseases, and gastrointestinal diseases. They specialize in bespoke solutions such as organoid models that simulate complex physiological systems, alongside GCLP-accredited laboratory services supporting clinical trials, which encompass histology, immunohistochemistry (IHC), gene expression, and DNA genotyping services.

Epistem serves a diverse clientele, including over 200 pharmaceutical and biotechnology companies, by providing reliable and transferable research models that address critical challenges in drug development. Their services are primarily marketed in North America, Europe, and Asia, facilitating collaboration with clients across these key regions. Epistem generates revenue through a service-based model, where clients engage the company for specialized research services and model development on a fee-for-service basis. For the most recent year, 2018, their revenue amounted to GBP 2,065,918.

70, with an EBITDA of GBP 12,051. 80. Transactions typically occur through direct contracts with pharmaceutical and biotechnology firms, which may involve project-based pricing or retainer agreements for ongoing support. The company's service offerings include flagship products such as advanced organoid models and comprehensive analytical platforms, which are priced according to the complexity and scope of the work required.

This structure allows Epistem to cater to clients' specific research needs while fostering long-term partnerships in the pharmaceutical sector. Epistem Ltd plans to continue its development of new research services and innovative models to cater to emerging demands in the biotechnology sector. The recent funding will likely be utilized to enhance their service offerings and expand into new geographical markets in North America and Asia. The company has a strategic goal to release new products by 2024, focusing on advanced organoid technologies that align with the industry's evolving needs.

The most recent PIPE funding on May 1, 2014, supported these development initiatives and overall operational growth.